Mary Honkanen, MD
Internal Medicine · Mobile, ALNPI 1316986052
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $246,406 of the $302,395 with a category attached, or 81.5%. 31 manufacturers reported payments, led by Novo Nordisk at 39.8% of the total. Reporting peaked in 2019 at $93,504 and has fallen 63.4% since, to $34,178 in 2025. Among internal medicine clinicians in AL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,051 payments — averaging $287.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$120K
- Amarin Pharma, Inc.$87K
- Amgen$62K
- Esperion Therapeutics, Inc.$15K
- Regeneron Healthcare Solutions, Inc.$5K
- Kowa Pharmaceuticals America, Inc.$4K
- plus $8K from 25 others
What the payments were for
- Consulting fees$2,5251%
- Speaking & faculty fees$246,40681%
- Travel & lodging$34,78612%
- Food & beverage$18,6576%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 286 | $120,279 |
| Amarin Pharma, Inc. | 258 | $87,276 |
| Amgen | 117 | $62,402 |
| Esperion Therapeutics, Inc. | 30 | $15,369 |
| Regeneron Healthcare Solutions, Inc. | 33 | $4,785 |
| Kowa Pharmaceuticals America, Inc. | 43 | $4,238 |
| Sanofi-aventis U.S. LLC | 21 | $3,172 |
| AstraZeneca | 47 | $1,311 |
| Lilly USA, LLC | 47 | $696 |
| Novartis | 52 | $621 |
| Bayer | 18 | $457 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 23 | $396 |
| Boehringer Ingelheim | 24 | $370 |
| Johnson & Johnson | 11 | $211 |
| Janssen Scientific Affairs, LLC | 1 | $124 |
| Xeris Pharmaceuticals, Inc. | 5 | $91 |
| Corcept Therapeutics | 5 | $89 |
| Dexcom, Inc. | 6 | $83 |
| Amryt Pharma Holdings Ltd | 4 | $74 |
| BD | 3 | $73 |
| Aegerion Pharmaceuticals, Inc. | 4 | $69 |
| Merck | 3 | $39 |
| Abbott | 1 | $25 |
| Tandem Diabetes Care, Inc. | 2 | $24 |
| Chiesi USA, Inc. | 1 | $22 |
| BETA Bionics, Inc. | 1 | $22 |
| Mannkind Corporation | 1 | $19 |
| Insulet Corporation | 1 | $17 |
| Medtronic | 1 | $14 |
| Currax Pharmaceuticals LLC | 1 | $13 |
| Lifescan, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$302,395 in reported general payments places this provider in the 95th percentile of 1,533 internal medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 309 | $429,248 |
| Repatha SureclickEvolocumab | 333 | $411,252 |
| VascepaIcosapent Ethyl | 406 | $281,285 |
| JardianceEmpagliflozin | 149 | $169,785 |
| FarxigaDapagliflozin Propanediol | 147 | $141,179 |
| Praluent PenAlirocumab | 73 | $85,572 |
| JanuviaSitagliptin Phosphate | 89 | $69,728 |
| Icosapent Ethyl | 140 | $60,157 |
| MounjaroTirzepatide | 40 | $55,487 |
| TrulicityDulaglutide | 16 | $20,937 |
| Ezetimibe | 890 | $20,281 |
| Victoza 2-PakLiraglutide | 13 | $11,301 |
| Rosuvastatin Calcium | 675 | $10,648 |
| Colesevelam Hcl | 13 | $6,462 |
| Fenofibrate | 223 | $5,790 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $120,279 | $429,248309 claims |
| Boehringer IngelheimJardiance | $370 | $169,785149 claims |
| AstraZenecaFarxiga | $1,311 | $141,179147 claims |
| Lilly USA, LLCMounjaro, Trulicity | $696 | $76,42356 claims |
| MerckJanuvia | $39 | $69,72889 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $4,238 | $3,29718 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,533 internal medicine providers in Alabama.
Other internal medicine in Mobile
- Thomas McKelveyMobile$365K
- Bobby WrightsMobile$89K
- Rahel AzizMobile$67K
- Jamie CaudillMobile$52K
- Lin LiMobile$45K
- Edward CarlosMobile$26K
- Donald SandersMobile$23K
- Amy StrassburgMobile$18K
- Roger AlvaradoMobile$18K
- Daniel PolanskyMobile$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.